Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial
单位：[1]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China[2]Shanghai Canc Ctr, Fudan Univ, Dept Urol, Shanghai, Peoples R China[3]Peking Univ First Hosp, Beijing, Peoples R China[4]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China[5]Tianjin Canc Hosp, Tianjin, Peoples R China[6]Jiangsu Prov Hosp, Nanjing, Peoples R China江苏省人民医院[7]Qilu Hosp Shandong Univ, Jinan, Peoples R China[8]Jiangxi Prov Tumour Hosp, Nanchang, Jiangxi, Peoples R China[9]Affiliated Tumor Hosp Affiliated Harbin Med Univ, Harbin, Peoples R China[10]Canc Hosp Henan Prov, Zhengzhou, Peoples R China河南省肿瘤医院[11]Liaoning Tumour Hosp, Shenyang, Peoples R China[12]Peking Union Med Coll Hosp, Beijing, Peoples R China[13]Gen Hosp Peoples Liberat Army China, Beijing, Peoples R China[14]Shengjing Hosp Affiliated China Med Univ, Shenyang, Peoples R China中国医科大学附属盛京医院中国医科大学盛京医院[15]Nanjing Bayi Hosp, Nanjing, Peoples R China[16]Tongji Hosp Affiliated Tongji Med Coll Huazhong U, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[17]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China[18]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China[19]Betta Pharmaceut Co Ltd, Hangzhou, Peoples R China
Guo Jun,Sheng Xinan,Ye Dingwei,et al.Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):doi:10.1200/JCO.2018.36.15_suppl.TPS4605.
APA：
Guo, Jun,Sheng, Xinan,Ye, Dingwei,He, Zhisong,Zhou, Ai-Ping...&Tan, Fenlai.(2018).Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA：
Guo, Jun,et al."Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018)
医学